

# PROGENE - National Study on Prostate Cancer

Head :Cussenot Olivier, CEREPP

Last update : 08/12/2014 | Version : 1 | ID : 60134

## General

### Identification

Detailed name National Study on Prostate Cancer

Sign or acronym PROGENE

CNIL registration number, number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency) authorisation CNIL: 27/06/2001

### General Aspects

Medical area Cancer research

Health determinants Genetic  
Social and psychosocial factors

Others (details) Prostate cancer

Keywords anatomopathological, data, weight, height, Health episodes, clinical, family history

### Scientific investigator(s) (Contact)

Name of the director Cussenot

Surname Olivier

Address 75020 PARIS

Phone + 33 (0)1 56 01 64 95

Email olivier.cussenot@tnn.aphp.fr

Unit CEREPP

Organization APHP

### Collaborations

### Funding

|  |   |
|--|---|
| Funding status   | Mixed   |
| Details  | AP-HP CEREPP  |
| <b>Governance of the database</b>                                      |   |
| Sponsor(s) or organisation(s) responsible                              | CEREPP  |
| Organisation status  | Private   |
| <b>Additional contact</b>  |   |
| <b>Main features</b>   |   |
| <b>Type of database</b>  |   |
| Type of database   | Study databases   |
| Study databases (details)  | Cohort study  |
| Database recruitment is carried out by an intermediary                 | A selection of health institutions and services   |
| Database recruitment is carried out as part of an interventional study | No  |
| Additional information regarding sample selection.                     | Inclusion method: Prospective Other bodies active in creating this cohort: CHU, CHG, INDEPENDENT PHYSICIANS, CNAM   |
| <b>Database objective</b>  |   |
| Main objective   | General objective: To initiate a collection of informative families with at least one member with prostate cancer and apparently health subjects.<br>Secondary objectives: - To identify genes for predisposition and susceptibility to prostate cancer<br>- To identify genetic markers associated with recurrence after treatment - To develop a genetic screening test for these pathologies |
| Inclusion criteria   | Men with histologically verified prostate cancer<br>Healthy subjects with PSA levels below 4 ng/ml  |
| <b>Population type</b>   |   |
| Age  | Adulthood (19 to 24 years)<br>Adulthood (25 to 44 years)<br>Adulthood (45 to 64 years)  |

|  |   |
|--|---|
| Population covered                           | Sick population   |
| Gender                                       | Male  |
| Geography area                               | National  |
| Detail of the geography area                 | France  |
| <b>Data collection</b>                       |   |
| <b>Dates</b>                                 |   |
| Date of first collection (YYYY or MM/YYYY)   | 06/2001   |
| <b>Size of the database</b>                  |   |
| Size of the database (number of individuals) | [1000-10 000[ individuals                               |
| Details of the number of individuals         | 5965  |
| <b>Data</b>                                  |   |
| Database activity                            | Data collection completed                               |
| Type of data collected                       | Clinical data<br>Declarative data<br>Biological data    |
| Clinical data (detail)                       | Direct physical measures<br>Medical registration        |
| Declarative data (detail)                    | Paper self-questionnaire                                |
| Biological data (detail)                     | Type of samples taken: Blood and/or saliva and/or urine |
| Presence of a biobank                        | Yes   |
| Contents of biobank                          | Serum<br>DNA  |
| Details of biobank content                   | Serum bank, DNA bank                                    |
| Health parameters studied                    | Health event/morbidity<br>Health event/mortality        |
| <b>Procedures</b>                            |   |
| Data collection method                       | Self-administered questionnaire: Entry from a paper     |

questionnaire (Manual input) Clinical examination:  
Handwritten (Manual input) Biological Analysis:  
Handwritten (Manual input)

Participant monitoring Yes

Details on monitoring of participants (Indefinite duration)

Links to administrative sources No

## Promotion and access

### Promotion

Link to the document <http://www.ncbi.nlm.nih.gov/pubmed/?term>

### Access

Terms of data access (charter for data provision, format of data, availability delay) Data may be used by academic teams. Access based on contract collaboration. Data may not be used by industrial teams

Access to aggregated data Access on specific project only

Access to individual data Access on specific project only